Cyclerion Therapeutics, Inc.
CYCN
$3.13
-$0.05-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.07M | 2.86M | 2.17M | 2.08M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.07M | 2.86M | 2.17M | 2.08M | 2.00M |
| Cost of Revenue | 959.00K | 496.00K | 229.00K | 278.00K | 286.00K |
| Gross Profit | 1.12M | 2.36M | 1.95M | 1.80M | 1.71M |
| SG&A Expenses | 6.09M | 5.99M | 5.70M | 5.27M | 5.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.05M | 6.49M | 5.93M | 5.55M | 5.63M |
| Operating Income | -4.97M | -3.63M | -3.76M | -3.47M | -3.63M |
| Income Before Tax | -3.53M | -2.20M | -1.95M | -2.94M | -3.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.53 | -2.20 | -1.95 | -2.94 | -3.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.53M | -2.20M | -1.95M | -2.94M | -3.06M |
| EBIT | -4.97M | -3.63M | -3.76M | -3.47M | -3.63M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.18 | -0.76 | -0.74 | -1.16 | -1.22 |
| Normalized Basic EPS | -1.00 | -0.74 | -0.73 | -0.73 | -0.76 |
| EPS Diluted | -1.18 | -0.76 | -0.74 | -1.16 | -1.22 |
| Normalized Diluted EPS | -1.00 | -0.74 | -0.73 | -0.73 | -0.76 |
| Average Basic Shares Outstanding | 12.66M | 11.39M | 10.70M | 10.13M | 10.07M |
| Average Diluted Shares Outstanding | 12.66M | 11.39M | 10.70M | 10.13M | 10.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |